Table 1 Clinical parameters of the study subjects
From: Circular RNA ciRs-126 promotes hypoxia/reoxygenation cardiac injury possibly through miR-21
Clinical parameters | H/R (n = 60) | Healthy subjects (n = 60) | P |
|---|---|---|---|
Sex (male/female) | 30/30 | 30/30 | 1.000 |
Age (years) | 52.1±6.7 | 52.0±6.8 | 0.643 |
Tobacco | 72% (43) | 58% (35) | 0.091 |
Hypertension | 76% (46) | 0 | ≠|
Hypercholesterolemia | 77% (46) | 0 | ≠|
Diabetes mellitus | 31% (19) | 0 | ≠|
Body mass index (kg/m2) | 23 ± 2,2 | 22 ± 1.8 | 0.000 |
Previous MI | 6% (4) | 0 | ≠|
Previous CABG | 1.6% (1) | 0 | ≠|
Previous PTCA | 0 | 0 | Â |
Glucose (mmol/L) | 3.1 ± 1.1 | 3.5 ± 0.2 | 0.000 |
High-sensitivity C-reactive protein (mg/L) | 15.13 ± 6.66 | 1.89 ± 1.36 | 0.000 |
LDH (U/L) | 481.60 ± 55.73 | 157.71 ± 22.94 | 0.000 |
CK-MB (U/L) | 118.29 ± 55.63 | 10.11 ± 2.16 | 0.000 |
cTnT (µg/L) | 21.44 ±5.95 | 0 | ≠|
Aspirin use | 56% (34) | 0 | ≠|
Clopidogrel use | 42% (25) | 0 | ≠|
Beta blocker use | 84% (50) | 0 | ≠|
Nitrates use | 77% (46) | 0 | ≠|
Angiotensin-converting-enzyme inhibitor drugs use | 30% (18) | 0 | ≠|
Angiotensin receptor blocker use | 11% (7) | 0 | ≠|
Calcium channel blocker use | 9% (5) | 0 | ≠|
Lipid-lowering drugs | 68% | 0 | ≠|